New study to see if suctioning out blood clots beats standard care for deep vein thrombosis

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-80, gender unrestricted; * Diagnosed as acute or subacute proximal deep venous thrombosis of the lower extremities through lower extremity venous ultrasound or enhanced CT of the lower extremity veins, with involvement of at least the common iliac vein, external iliac vein, or common femoral vein; * The subjects met the criteria for standard anticoagulation therapy combined with thrombus aspiration along with standard anticoagulation therapy; * The patient fully understands and voluntarily signs a written informed consent form; * Willing and able to comply with all the visit, treatment, and assessment procedures specified in the study protocol. Exclusion Criteria: * Bilateral deep iliofemoral vein thrombosis; * Femoral edema or femoral white swelling; * Inferior vena cava thrombosis; * History of deep vein thrombosis with a diagnosis of moderate to severe post-thrombotic syndrome; * The affected limb has previously had a venous stent implanted; * There are anatomical abnormalities affecting the intervention pathway, such as hypoplasia or dysplasia of the inferior vena cava, or other malformations of the iliac or inferior vena cava; * Presence of active major bleeding or clinically significant bleeding risk (hemoglobin \<80g/L or platelet count \<50×109/L); * Severe coagulation dysfunction, with an international normalized ratio \>1.7; * Uncontrolled severe hypertension (systolic blood pressure \>180 mmHg or diastolic blood pressure \>105 mmHg after medication); * Severe renal impairment, with a glomerular filtration rate \<30 mL/min/1.73m²; * Any interventional treatment for the target deep vein thrombosis within 30 days prior to enrollment; * Female patients in pregnancy or lactation; * Known history of allergies to drugs used during the study (such as contrast agents, anticoagulants, etc.); * Active malignant tumor; * In the judgment of the researchers, there are any other comorbidities, conditions, or poor adherence that may affect the study evaluation or place the patient at high risk.